Mochida Pharmaceutical Co., Ltd. (TYO:4534)
Japan · Delayed Price · Currency is JPY 3,355.00
+5.00 (0.15%)
Nov 13, 2026, 3:30 PM JST
Mochida Pharmaceutical Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 126,332 | 116,951 | 105,159 | 102,885 | 103,261 | 110,179 |
Revenue Growth | 15.85% | 11.21% | 2.21% | -0.36% | -6.28% | 6.98% |
Gross Profit Gross Profit Growth | 59,500 | 56,261 | 53,788 | 52,070 | 55,115 | 59,553 |
Operating Income Operating Income Growth | 12,284 | 10,148 | 8,127 | 5,803 | 8,508 | 14,392 |
Net Income Net Income Growth | 10,754 | 7,903 | 5,685 | 4,547 | 6,649 | 10,569 |
Earnings Per Share EPS Growth | 304.00 | 222.93 | 160.36 | 126.79 | 178.93 | 277.39 |
EPS Growth | 60.47% | 39.02% | 26.48% | -29.14% | -35.49% | 24.80% |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Pharmaceutical Pharmaceutical Growth | 117,972 | 109,042 | 97,989 | 96,455 | 97,340 | 104,447 |
Healthcare Business Healthcare Business Growth | 8,360 | 7,908 | 7,169 | 6,430 | 5,920 | 5,732 |
Total Total Growth | 126,332 | 116,950 | 105,158 | 102,885 | 103,260 | 110,179 |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 28,572 | 31,057 | 51,150 | 46,789 | 60,509 | 61,914 |
Total Debt Total Debt Growth | 10,000 | 10,000 | - | - | - | - |
Net Cash (Debt) Net Cash Growth | 18,572 | 21,057 | 51,150 | 46,789 | 60,509 | 61,914 |
Net Cash Growth | -64.77% | -58.83% | 9.32% | -22.67% | -2.27% | -2.48% |
Net Cash Per Share Net Cash Per Share Growth | 525.00 | 593.99 | 1442.84 | 1304.66 | 1628.34 | 1624.95 |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -12,248 | -7,350 | 9,354 | -7,480 | 7,297 | 7,459 |
Capital Expenditures CapEx Growth | -2,194 | -2,695 | -2,160 | -2,296 | -2,166 | -2,988 |
Free Cash Flow Free Cash Flow Growth | -14,442 | -10,045 | 7,194 | -9,776 | 5,131 | 4,471 |
Free Cash Flow Growth | - | - | - | - | 14.76% | -38.44% |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 47.10% | 48.11% | 51.15% | 50.61% | 53.37% | 54.05% |
Operating Margin | 9.72% | 8.68% | 7.73% | 5.64% | 8.24% | 13.06% |
Pretax Margin | 11.98% | 9.55% | 7.66% | 5.99% | 8.76% | 13.24% |
Profit Margin | 8.51% | 6.76% | 5.41% | 4.42% | 6.44% | 9.59% |
FCF Margin | -11.43% | -8.59% | 6.84% | -9.50% | 4.97% | 4.06% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 15, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 85.000 | 80.000 | 80.000 | 80.000 | 80.000 | 90.000 |
Dividend Per Share Growth | 6.25% | 0% | 0% | 0% | -11.11% | 0% |
Dividend Yield | 2.53% | 2.31% | 2.52% | 2.48% | 2.50% | 2.39% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 15, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 11.04 | 15.52 | 19.83 | 25.13 | 17.58 | 13.38 |
Forward PE | - | 18.59 | 18.59 | 20.70 | 18.73 | 15.31 |
P/FCF Ratio | - | - | 15.67 | - | 22.78 | 31.64 |
PS Ratio | 0.93 | 1.05 | 1.07 | 1.11 | 1.13 | 1.28 |